GLP-1 – Medxy AI

Serum GLP-1 as a Novel Biomarker for Endometrial Cancer Detection in Obese Women

By MedXY 10/04/2026

This study reveals that lower serum GLP-1 levels are independently associated with endometrial cancer in obese, non-diabetic women, suggesting its potential as a diagnostic biomarker with high sensitivity and specificity.

Diabetes & Endocrinology Internal Medicine news

Adult Overweight and Obesity Management: Key Updates from the 2025 VA/DoD Clinical Practice Guideline

By MedXY 08/27/2026

A clear, clinician-focused summary of the 2025 VA/DoD guideline update: new screening thresholds, streamlined treatment pathways, integration of pharmacotherapy (including GLP‑1 receptor agonists), endoscopic and surgical options, and veteran-centered care.

Diabetes & Endocrinology Gastroenterology news

An Obesity Subphenotype With Low Endogenous GLP-1 Production Shows Markedly Greater Weight Loss With Tirzepatide

By MedXY 06/10/2026

A 2026 study identifies a biologically distinct obesity subphenotype marked by fast gastric emptying, low GLP-1 synthesis, and substantially greater 6-month weight loss with tirzepatide.

Clinical Updates Diabetes & Endocrinology news

Synergistic Protection of Pancreatic Beta Cells: GLP1-E2 and Low-Dose Anti-CD3 Combination Therapy in Autoimmune Diabetes

By MedXY 05/20/2026

Recent studies demonstrate that combining the beta-cell-targeted conjugate GLP1-E2 with low-dose anti-CD3 therapy significantly delays type 1 diabetes onset by simultaneously reducing immune infiltration and mitigating beta-cell cellular stress.

Diabetes & Endocrinology news Public Health

Managing Obesity as a Chronic Disease: The 2026 WHO Guidelines on GLP-1 Therapies

By MedXY 02/05/2026

The World Health Organization (WHO) has released its landmark 2026 guidelines on GLP-1 therapies for obesity, reclassifying the condition as a chronic, relapsing disease requiring long-term pharmacological and behavioral management while emphasizing global health equity.

Clinical Updates Diabetes & Endocrinology news

Frontiers in Cardiometabolic Medicine: From Oral GLP-1 Small Molecules to RNAi Therapeutics

By MedXY 01/17/2026

This review synthesizes recent breakthroughs in obesity, type 2 diabetes, and lipidology, focusing on oral orforglipron, zodasiran for HoFH, and adolescent metabolic risk factors.

Diabetes & Endocrinology Internal Medicine news

Dietary Phytomix Dibifree Reshapes T2D Management by Modulating the Gut-Pancreas-Adipose-Immune Axis

By MedXY 01/11/2026

A randomized trial demonstrates that Dibifree, a novel dietary phytomix, improves HbA1c and adiposity in T2D patients by enhancing GLP-1 activity and modulating immune responses.

Clinical Updates Diabetes & Endocrinology news

What’s New in the ADA 2024 Standards of Care: Practical Guidance on Weight‑Lowering Drugs, Cardiorenal Protection, and Technology for Diabetes

By MedXY 09/26/2025

The ADA 2024 Standards update care pathways for diabetes with stronger guidance on obesity pharmacotherapy (GLP‑1/GIP agents), earlier use of SGLT2/GLP‑1 for cardiorenal benefit, and expanded technology recommendations.

Clinical Updates Gastroenterology Internal Medicine news Specialties

HEC88473 Dual GLP-1/FGF21 Agonist: Advancing Treatment for MASLD and T2DM with Promising Safety and Efficacy

By MedXY 09/20/2025

A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatment.

Clinical Updates news

Dapagliflozin’s Effects on Hormonal Regulation and Ketone Production in Adults with Type 1 Diabetes: Insights from a Randomised Controlled Crossover Trial

By MedXY 09/17/2025

This trial evaluates dapagliflozin's impact on key hormones and ketogenesis in type 1 diabetes, demonstrating increased ketone bodies without altering GLP-1, glucagon, or somatostatin secretion, highlighting risks and benefits for adjunct therapy.

Clinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Enhancing Metformin Efficacy and Tolerability in Prediabetes Through a Fermentable Carbohydrate-Rich Diet

By MedXY 09/17/2025

A fermentable carbohydrate-enriched diet combined with metformin improves postprandial glycaemia, enhances GLP-1 secretion, and positively alters gut microbiota in prediabetic individuals, offering a personalized nutrition-pharmacology strategy for diabetes prevention.

Diabetes & Endocrinology news Specialties

What’s New in Diabetes Care: Key Changes from the ADA 2024 Standards of Care

By MedXY 09/07/2025

A clinician-friendly summary of the American Diabetes Association’s 2024 Standards: who to screen, modern use of GLP‑1/GIP agents and SGLT2 inhibitors, continuous glucose monitoring, weight-management drugs, and implications for practice.

Diabetes & Endocrinology Specialties

What’s New in Diabetes Care 2024: Key Recommendations from the ADA Standards of Care

By MedXY 08/22/2025

A practical, clinician-friendly summary of the American Diabetes Association’s 2024 Standards of Care, highlighting new recommendations on GLP-1/GIP therapy, SGLT2 inhibitors, continuous glucose monitoring, and individualized care.

Diabetes & Endocrinology Specialties

ADA Standards of Care 2024: A Clinician-Friendly Guide to the New Cardiorenal‑Metabolic Era in Diabetes Care

By MedXY 08/22/2025

The ADA's 2024 Standards refocus diabetes care around cardiorenal protection, expanded use of GLP‑1 and SGLT2 therapies, wider adoption of glucose‑sensing technology, and integrated obesity management.

Diabetes & Endocrinology news Specialties

Synergistic Effects of Metformin and Moderate FODMAP Diet in Improving Postprandial Glycemia and Gut Health in Prediabetes

By MedXY 08/17/2025

Combining metformin with a moderate FODMAP diet improves postprandial glucose control, enhances GLP-1 secretion, increases butyrate-producing gut bacteria, and reduces inflammation without worsening gastrointestinal side effects in prediabetic patients.

Clinical Updates news Ophthalmology Otorhinolaryngology Specialties

GLP-1 Receptor Agonists Linked to Early Risk of Optic Nerve Damage: A Case-Control Study Analysis

By MedXY 07/30/2025

GLP-1 receptor agonist use, especially liraglutide, is associated with a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION) during the first year, particularly in patients without diabetes or obesity.

Diabetes & Endocrinology news Specialties

The Rise of Ozempic and Wegovy: Revolutionizing Weight Loss, But At What Cost?

By MedXY 07/28/2025

Semaglutide drugs like Ozempic and Wegovy are transforming obesity treatment, but questions remain about long-term safety, access, and societal impact.

Cardiology Diabetes & Endocrinology news

Ozempic and the Weight Loss Revolution: Miracle Drug or Medical Hype?

By MedXY 07/28/2025

Exploring the science, benefits, risks, and realities behind Ozempic and other GLP-1 drugs in the fight against obesity.

Diabetes & Endocrinology news

The End of the Diet? Inside the Game-Changing Anti-Obesity Drug Revolution

By MedXY 07/25/2025

New anti-obesity medications are transforming weight management, challenging old paradigms, and raising new questions about the future of dieting and health.